Huntington's Disease Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Huntington's Disease market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as MicuRx, Basilea pharmaceuticals, AbbVie, Cubist Pharms LLC, Nabriva Therapeutics, Melinta Therapeutics, Durata Therapeutics, SOM Innovation Biotech SA Hoffmann-La Roche, Sage Therapeutics, UniQure Biopharma B.V., Ionis Pharmaceuticals, Inc., Pfizer, Vaccinex Inc.

[Nevada, United States] - DelveInsight's "Huntington's Disease Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Huntington's Disease, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Huntington's Disease Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Huntington's Disease Market Report:
• The Huntington's Disease market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Hoffmann-La Roche announced that a Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals With Prodromal and Early Manifest Huntington's Disease
• In October, 2024: PTC Therapeutics announced a Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD). The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
• In October, 2024: UniQure Biopharma B.V. announced that their study is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase I/II, randomized, multicenter, multiple dose, double-blind, imitation surgery, first-in-human (FIH) study.
• In September, 2024: Sage Therapeutics announced that the purpose of their study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
• In July, 2024: Wave Life Sciences Ltd. announced that a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and PD of WVE-003 in adult patients with early-manifest HD who carry the targeted single nucleotide polymorphism (SNP) - SNP3.
• Globally, HD affects approximately 5 to 10 per 100,000 people. The prevalence varies by region, with higher rates in Europe and North America compared to Asia and Africa.
• Huntington's disease is caused by a mutation in the HTT gene, leading to abnormal repetitions of the CAG sequence. Individuals with 40 or more repeats are likely to develop the disease.
• Symptoms generally begin between the ages of 30 and 50, though there are juvenile forms of the disease, which account for about 5-10% of cases.
• Key Huntington's Disease Companies are as follows: MicuRx, Basilea pharmaceuticals, AbbVie, Cubist Pharms LLC, Nabriva Therapeutics, Melinta Therapeutics, Durata Therapeutics, SOM Innovation Biotech SA Hoffmann-La Roche, Sage Therapeutics, UniQure Biopharma B.V., Ionis Pharmaceuticals, Inc., Pfizer, Vaccinex Inc.
• Key Huntington's Disease Therapies are as follow: AUSTEDO (deutetrabenazine/SD-809), INGREZZA (valbenazine/NBI-98854), Pridopidine (ACR-16), ANX005, SOM3355, RO7234292, SAGE-718, ISIS 443139, Pridopidine ,Dimebon, PF-02545920, VX15/2503, Tominersen, ANX005
• Launching multiple stage Huntington's Disease pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Huntington's Disease market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Huntington's Disease Overview:
Huntington's disease is inherited as an autosomal dominant trait. In dominant disorders, a single copy of the disease gene (received from either the mother or father) will be expressed "dominating" the other normal gene, resulting in the appearance of the disease. Huntington's disease is caused by variations (mutations) of a gene (huntingtin) that is located on the short arm (p) of chromosome 4 (4p16.3).

Huntington's Disease Epidemiology Segmentation:
The Huntington's Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Huntington's Disease Total Prevalence
• Huntington's Disease Prevalent Cases by severity
• Huntington's Disease Gender-specific Prevalence
• Huntington's Disease Diagnosed Cases of Episodic and Chronic

For more information about Huntington's Disease companies working in the treatment market, visit https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Huntington's Disease Market Insights
The global Huntington's disease market is projected to grow significantly due to advancements in research, increased awareness, and the approval of new treatments. Factors driving this growth include: The Huntington's disease market was valued at approximately USD 300 million in 2023 and is expected to grow at a CAGR of 12-15% during the forecast period (2023-2030).
Leading companies include Teva Pharmaceuticals, H. Lundbeck A/S, UniQure, Sangamo Therapeutics, Roche, and Ionis Pharmaceuticals.

Huntington's Disease Drugs Uptake
• Tetrabenazine (Xenazine): Used to treat chorea (involuntary movements), this drug depletes dopamine in the brain.
• Deutetrabenazine (Austedo): An advanced form of tetrabenazine that offers a better safety profile with reduced dosing frequency.
• ntipsychotics (e.g., olanzapine): Frequently prescribed to manage psychiatric symptoms like agitation and hallucinations.
• Gene Silencing Therapies: Drugs like IONIS-HTTRx and Wave Life Sciences' allele-selective treatments target the reduction of mutant huntingtin protein, aiming to slow disease progression.
• Gene Therapy: UniQure's AMT-130, an investigational gene therapy, aims to provide long-lasting reductions in huntingtin protein through a one-time viral vector injection.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Huntington's Disease Therapies and Key Companies:
• AUSTEDO (deutetrabenazine/SD-809): Teva Pharmaceutical
• INGREZZA (valbenazine/NBI-98854): Neurocrine BiosciencesPridopidine (ACR-16): Prilenia Therapeutics
• ANX005: Annexon Biosciences
• SOM3355: SOM Innovation Biotech SA
• RO7234292: Hoffmann-La Roche
• SAGE-718: Sage Therapeutics
• ISIS 443139: Ionis Pharmaceuticals, Inc.
• Pridopidine: Prilenia
• Dimebon: Medivation, Inc.
• PF-02545920: Pfizer
• VX15/2503: Vaccinex Inc.
• Tominersen: Hoffmann-La Roche
• ANX005: Annexon, Inc.

Huntington's Disease Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Huntington's Disease.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Huntington's Disease Market Drivers:
• Advancements in Gene Therapy
• Increasing Research Funding
• Growing Awareness
• Biomarker Development

Huntington's Disease Market Barriers:
• High Cost of Therapies
• Limited Awareness in Developing Regions
• Lack of Curative Treatments
• Regulatory Hurdles

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Huntington's Disease Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Huntington's Disease Companies: MicuRx, Basilea pharmaceuticals, AbbVie, Cubist Pharms LLC, Nabriva Therapeutics, Melinta Therapeutics, Durata Therapeutics, SOM Innovation Biotech SA Hoffmann-La Roche, Sage Therapeutics, UniQure Biopharma B.V., Ionis Pharmaceuticals, Inc., Pfizer, Vaccinex Inc.
• Key Huntington's Disease Therapies: AUSTEDO (deutetrabenazine/SD-809), INGREZZA (valbenazine/NBI-98854), Pridopidine (ACR-16), ANX005, SOM3355, RO7234292, SAGE-718, ISIS 443139, Pridopidine ,Dimebon, PF-02545920, VX15/2503, Tominersen, ANX005
• Huntington's Disease Therapeutic Assessment: Current marketed and emerging therapies
• Huntington's Disease Market Dynamics: Huntington's Disease Market drivers and Huntington's Disease barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Huntington's Disease Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Huntington's Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Huntington's disease Market Overview at a Glance: By Country
4. Executive Summary of Huntington's disease
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. Huntington's disease: 7 Major Market Analysis
13. Market Access and Reimbursement
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.